Targets › GYPC
3 programs from 3 companies in 3 trials: 3 Phase 1; Oncology; next expected readout Mar 2027.
This protein is a minor sialoglycoprotein in human erythrocyte membranes. The blood group Gerbich antigens and receptors for Plasmodium falciparum merozoites are most likely located within the extracellular domain. (UniProt, P04921)
Open in Phaseline: the race on GYPC, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Beijing Biotech | EB-DTNB-NK Dual-target GD2/B7-H3 CAR-NK cells with IL-15 support and inducible safety switch | GYPC, CD276 | Phase 1 | Relapsed Neuroblastoma | Mar 2027 |
| Sun Yat-Sen University Cancer Center | GD2/B7H3 CAR-T cell therapy Dual-targeted CAR-T cells recognizing GD2 and B7H3 antigens | GYPC, B7H3 | Phase 1 | Neuroblastoma (NB) | Dec 2027 |
| Baylor College of Medicine | iC9-GD2 T Cells GD2-targeting chimeric antigen receptor (CAR) T cells with iCaspase-9 suicide safety switc | GYPC | Phase 1 | Neuroblastoma | Oct 2030 |
Neuroblastoma (1) Relapsed Neuroblastoma (1) Neuroblastoma (NB) (1)
mixed (2), other (1)
Baylor College of Medicine (1) Beijing Biotech (1) Sun Yat-Sen University Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.